头孢他啶-阿维巴坦与美罗培南对泛耐药、产碳青霉烯酶、被研究使用时间杀伤和药敏纸片近似法测定的菌株的协同作用。
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring and Investigated Using Time-Kill and Disk Approximation Assays.
机构信息
Laboratório de Investigação Médica 54 (LIM-54), Instituto de Medicina Tropical, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Divisão de Laboratório Central - Serviço de Microbiologia Clínica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
出版信息
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02367-18. Print 2019 May.
Abstract
Susceptibility of ceftazidime-avibactam and synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant isolates harboring oxacillinases and 5 isolates carrying Ceftazidime-avibactam was very active and synergistic with meropenem against multiresistant isolates. On the other hand, only the isolates coharboring and displayed synergy. The disk approximation technique presented good sensitivity for synergism in infection.
摘要
采用纸片琼脂扩散法和时间杀菌法，检测了头孢他啶-阿维巴坦的药敏性及其与美罗培南的协同作用，共检测了 11 株携带耐甲氧西林酶的多耐药株和 5 株携带头孢他啶-阿维巴坦的耐药株。头孢他啶-阿维巴坦对多耐药株非常有效，并与美罗培南具有协同作用。另一方面，只有同时携带 和 的耐药株显示出协同作用。纸片琼脂扩散法在 感染中对协同作用具有良好的敏感性。
相似文献
1
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring and Investigated Using Time-Kill and Disk Approximation Assays.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02367-18. Print 2019 May.
2
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02255-19.
3
Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
4
In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates.
J Glob Antimicrob Resist. 2019 Jun;17:137-141. doi: 10.1016/j.jgar.2018.12.004. Epub 2018 Dec 18.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems.
Int J Antimicrob Agents. 2024 Aug;64(2):107257. doi: 10.1016/j.ijantimicag.2024.107257. Epub 2024 Jun 23.
7
Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype.
mSphere. 2018 Sep 26;3(5):e00408-18. doi: 10.1128/mSphere.00408-18.
8
Antimicrobial activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant and - a pilot Bulgarian study.
Infect Dis (Lond). 2019 Nov-Dec;51(11-12):870-873. doi: 10.1080/23744235.2019.1653491. Epub 2019 Aug 21.
9
Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Microb Drug Resist. 2018 Jan/Feb;24(1):35-39. doi: 10.1089/mdr.2016.0293. Epub 2017 Jun 7.
10
synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant .
J Med Microbiol. 2020 Jul;69(7):928-931. doi: 10.1099/jmm.0.001211.
引用本文的文献
1
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.
J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451.
2
Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Patient Isolates.
Microorganisms. 2024 Jul 2;12(7):1353. doi: 10.3390/microorganisms12071353.
3
Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis.
Infection. 2024 Oct;52(5):2029-2042. doi: 10.1007/s15010-024-02277-y. Epub 2024 May 13.
4
A Sixty-Nine-Year-Old Female With Serratia marcescens Infection.
Cureus. 2023 Dec 5;15(12):e49985. doi: 10.7759/cureus.49985. eCollection 2023 Dec.
5
In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.
Infection. 2022 Jun;50(3):569-581. doi: 10.1007/s15010-021-01748-w. Epub 2022 Jan 4.
6
Quercetin Rejuvenates Sensitization of Colistin-Resistant and Clinical Isolates to Colistin.
Front Chem. 2021 Nov 25;9:795150. doi: 10.3389/fchem.2021.795150. eCollection 2021.
7
Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant .
Antibiotics (Basel). 2021 Nov 3;10(11):1344. doi: 10.3390/antibiotics10111344.
8
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.
Infect Drug Resist. 2020 Jun 12;13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.
9
Molecular Characterization of Carbapenem-Resistant Clinical Isolates in a Tertiary Hospital in Hangzhou, China.
Infect Drug Resist. 2020 Apr 7;13:999-1008. doi: 10.2147/IDR.S243197. eCollection 2020.
本文引用的文献
1
Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype.
mSphere. 2018 Sep 26;3(5):e00408-18. doi: 10.1128/mSphere.00408-18.
2
Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.
Int J Antimicrob Agents. 2018 Jul;52(1):82-85. doi: 10.1016/j.ijantimicag.2018.02.017. Epub 2018 Feb 27.
3
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
4
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
5
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01964-16. Print 2017 Feb.
6
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
7
Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms.
PLoS One. 2016 Mar 21;11(3):e0151270. doi: 10.1371/journal.pone.0151270. eCollection 2016.
8
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
9
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.
10
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
Int J Antimicrob Agents. 2016 Mar;47(3):235-42. doi: 10.1016/j.ijantimicag.2016.01.004. Epub 2016 Feb 3.
Zotero 插件